Urgent health risks from Airborne viruses; How UV Flu Technologies, Inc. (OTCBB: UVFT innovative new air purification technology is more effective than filtering

Point Roberts WA - November 30, 2010 – www.Investorideas.com, an investor research portal specialized in sector investing, issues biotech stocks commentary by Lisa Springer, CFA, equity research analyst and financial writer. The report entitled,' Urgent Health Threat from Airborne Viruses ‘, features UV Flu Technologies, Inc. UVFT and its air purification technology. Urgent Health Threat from Airborne Viruses Lisa Springer, CFA, Equity research analyst and financial writer Stocks in this report: UV Flu Technologies, Inc. UVFT, Pall Corp PLL, Donaldson Company DCI There is an urgent health threat deadlier than the H1N1 pandemic on the rise, yet few Americans are aware of it. The threat comes from infections acquired while in the hospital. According to a recent government study, America's hospitals aren't adequately protecting patients from these potentially deadly infections. A 2009 report by the US Health and Human Services department found little progress has been made over the past decade in eliminating hospital-acquired infections and urged Congress to take action. As many as 98,000 Americans die each year from medical errors and preventable infections are a major contributor to the problem. Ten years ago, the Institute of Medicine launched a campaign to stamp out hospital-acquired infections, but the success of their initiatives has been minimal. The latest report showed three of five major types of hospital-acquired infections have actually become more prevalent, one showed no progress and only one declined. Bloodstream infections, which are considered the most serious and potentially fatal, rose 8.0 percent. There was also a sizable 3.6 percent increase in the incidence of urinary tract infections. While generally responsive to antibiotics, urinary tract infections increase hospitalization time and costs. Overall, the incidence of common hospital-acquired infections was up 1.6 percent. Media coverage of hospital-acquired infections, the swine flu pandemic and antibiotic resistant superbugs is raising consumer awareness and spurring government agencies and businesses to take action to safeguard public health. Demand for products that prevent the spread of airborne illnesses is rising exponentially. The swine flu pandemic created a $7 billion windfall for vaccine manufacturers, according to the Wall Street Journal, and a bonanza for makers of hand sanitizers, who experienced a 129% jump in shipments during last year's flu season. This heightened awareness is also spreading to the nearly $8 billion annual market for indoor air quality products. These products improve air quality in commercial buildings, hospitals, schools and homes by removing airborne pathogens. Scientific studies show poor indoor air quality is a major reason for the spread of infectious disease. According to the Environmental Protection Agency, the air inside buildings where people spend 90% of their time now poses a greater threat than outdoor air. Most air quality systems use a simple filter (either standard or HEPA) to trap pathogens. Well-known filter device manufacturers include Pall Corp PLL, Donaldson Company DCI and Millipore, which was recently acquired by Merck KGaA. A relative newcomer to this market, UV Flu Technologies, Inc. UVFT, has developed an innovative new air purification technology that is more effective than filtering. This technology disinfects indoor air by deactivating allergens and killing airborne pathogens, including bacteria, viruses and mold. UV Flu Technologies flagship product, the ViraTech UV-400, uses high intensity germicidal UV radiation inside a killing chamber to trap and destroy harmful microbes. Extensive independent testing by EPA and FDA certified laboratories confirms UV Flu Technologies system captures and kills airborne bacteria and viruses at rates exceeding 99.2% on a first pass basis. The technology is so effective that UV Flu Technologies was able to secure a Class II medical listing enabling it to market its product as a medical device. Since introducing its flagship device less than one year ago, UV Flu Technologies has sold units to multiple sports teams, hospitals, restaurants and other commercial customers. Two professional hockey teams (including the renowned Boston Bruins) and numerous college teams have installed ViraTech UV-400 units in their locker rooms. In addition, the company has installed units at two major hospitals and has units being evaluated by a large nursing home chain. Hospitality customers such as The Seagate Hotel and Spa in Delray Beach, Florida, the Boston Harbor Hotel and Boston's XV Beacon Hotel have installed ViraTech UV-400 units and one of the nation's largest 5 star hotels is evaluating the unit for its operations. Tests of units are also underway with one of the largest hotel and restaurant suppliers in the Northeast. In addition, "Clean Air for Everyone," a non-profit promoting clean air for schools and non-profits across America recently selected the ViraTech UV-400 as its lead product for national rollout. UV Flu Technologies plans to expand its product line and distribution capabilities by acquiring a major US manufacturer of high quality air purification equipment. The company hopes to complete the merger this year. Included in the agreement is a patented product line, national distribution network, and installed base of several thousand units across 1,000 unique facilities nationwide. UVFT President Jack Lennon notes that the expanded product line will make the company more attractive to large US distributors and improve its visibility in the hospital, hotel and casino markets. UV Flu Technologies is also expanding its sales channels by adding three new distributors. The new distributors are Emerald Medical Service, a supplier of medical equipment serving the Washington, DC area; UV Air, a supplier to government, schools, and hotels in Massachusetts and Factory-Direct Green, a distributor servicing over 400 hotel customers in California. Lisa Springer, CFA -Bio and disclaimer: http://www.investorideas.com/About/Lisa-Springer-CFA/ The author, Lisa Springer, was compensated for writing this article and doesn't own shares of any of the companies mentioned in this article. About UV Flu Technologies, Inc. UVFT UV Flu Technologies is an innovative developer, manufacturer and distributor of bio technology products initially targeting the rapidly growing Indoor Air Quality ("IAQ") industry sector (over $7.7 billion in 2008). The Company manufactures the ViraTech UV-400, which utilizes high- intensity ultraviolet radiation (UV-C) inside a killing chamber that goes beyond filtration to destroy harmful airborne bacteria, at rates exceeding 99.2% on a first-pass basis, while also reducing the concentrations of odors, and VOC's (volatile organic compounds, such as acetone, benzene, formaldehyde, etc.) The FDA has issued a coveted Class II medical listing that enables UV Flu Technologies to market the product as a medical device. For more information, visit: www.uvflutech.com. For sales: www.puravair.com. Read the forward looking statements disclaimer on all company press releases and company website. UV Flu Technologies UVFT is a showcase biotech stock on Investorideas.com Visit the showcase page on Investorideas.com http://www.investorideas.com/CO/UVFT/ Request info: http://www.investorideas.com/Resources/Newsletter.asp UV Flu Technologies, Inc. Contact: Investor Information: Geaux IR Services, Inc. Toll-Free: 1-888-355-8838 investors@uvflutech.com About InvestorIdeas.com: InvestorIdeas.com is a leading global investor and industry research resource portal specialized in sector investing, covering leading industry sectors including biotech stocks. Research more biotech stocks at the Biotech stocks Directory: http://www.investorideas.com/BIS/Stock_List.asp Disclaimer: The following news is paid for by third party on behalf of UV Flu Technologies, Inc., (three thousand per month) Lisa Springer CFA- Investorideas compensated three hundred fifty for article. Investorideas.com is a third party publisher of news and research .Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising. Contact Investorideas.com cvanzant@investorideas.com 800 665 0411